OVID THERAPEUTICS INC
OVIDNASDAQTrading Snapshot
- Day Range
- $2.51 – $2.59
- 52-Week Range
- $1.18 – $3.11
- Volume
- $1.88B
- Avg Volume
- $1.49B
- Shares Outstanding
- 186.6M
- Next Earnings
- Nov 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $733,000
- P/E Ratio
- -5.3
- P/S Ratio
- 299.5x
- EPS (TTM)
- $-0.47
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +15.0%
Why Investors Own OVID
- ✓High-growth profile — revenue up +1.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
OVID THERAPEUTICS INC
OVID
StockOtter · stockotter.spaceAbout OVID THERAPEUTICS INC
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today ann
BlackRock Inc. Takes Position in Ovid Therapeutics $OVID
BlackRock Inc. bought a new position in shares of Ovid Therapeutics (NASDAQ: OVID) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The instit
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today prov
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.